Skip to main content
SpringerLink
Log in

Decision Analysis of Histamine H2-Receptor Antagonist Maintenance Therapy Versus Helicobacter pylori Eradication Therapy

A Randomised Controlled Trial in Patients with Continuing Pain After Duodenal Ulcer

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background: Much has been published on the efficacy and cost effectiveness of Helicobacter pylori eradication treatment as an alternative to histamine H2-receptor antagonist maintenance treatment in peptic ulcer disease. However, most studies have analysed and emphasised H. pylori eradication rates rather than management/control of symptoms and the associated cost savings. Although H. pylori eradication therapy is very successful in clearing the infection, dyspeptic symptoms may persist and management of these can be expensive.

Objective: The aim of this studywas to assess the cost implications in controlling symptoms using either H2-receptor antagonist maintenance therapy or H. pylori eradication therapy in patients with duodenal ulcer disease.

Design: This was a non-blind, prospective, randomised, parallel-group study comparing maintenance H2-receptor antagonist treatment using ranitidine with H. pylori eradication therapy, with a 1-year follow-up.

Setting: This was a study of outpatients from general practices in Dundee, Scotland, or the Ninewells Hospital, Dundee, gastroenterology clinic.

Patients and participants: 119 patientswith confirmed duodenal ulcer, free from active ulceration at study entry but positive for H. pylori infection, who were receiving maintenance H2-receptor antagonist therapy.

Interventions: Patients were randomised to receive either continuing maintenance therapy with ranitidine (initially 150mg daily; 58 patients) or H. pylori eradication therapy using an omeprazole/amoxicillin/metronidazole regimen (or omeprazole/clarithromycin if allergic to penicillin).

Main outcome measures and results: Overall, H. pylori eradication rates were 100% per protocol and 95.1% intention-to-treat. At completion of 1 year of follow-up, 12 of the 61 (19.7%) patients successfully eradicated of H. pylori were still dependent on acid suppression for symptom relief. H. pylori eradication treatment was the least-cost strategy in managing/controlling symptoms at 1 year (£168 vs £210 per patient; 1996 values). However, over time, post-eradication treatment costs were greater than H2-receptor antagonist therapy costs. Any potential savings were directly related to the proportion of patients needing further treatment post-eradication, the cost of endoscopy and the urea breath test.

Conclusions: If dyspepsia persists long term, H. pylori eradication treatment may not be the least-cost option for patients with duodenal ulcer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ryder S, O’Reilly S, Miller R, et al. Long term acid suppressing drugs in general practice. BMJ 1994; 308: 827–30

    Article  PubMed  CAS  Google Scholar 

  2. Moore RA. Helicobacter pylori and peptic ulcer: Oxford: Health Technology Evaluation Association, 1995

    Google Scholar 

  3. Dixon JS, Wood JR. Geographical variation in duodenal ulcer healing in patients treated with H2 receptor antagonists. Eur J Gastroenterol Hepatol 1992; 4: 147–63

    Google Scholar 

  4. Hunt RH, Cederberg C, Dent J, et al. Optimizing acid suppression for treatment of acid-related diseases. Dig Dis Sci 1995; 40 (2 Suppl): 24S-49S

    Article  Google Scholar 

  5. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996; 110: 2–83

    Article  Google Scholar 

  6. McIntyre A-M, MacGregor S, Malek M, et al. New patients presenting to their GP with dyspepsia: does Helicobacter pylori eradication minimise the cost of managing these patients? Int J Clin Pract 1997; 51: 276–81

    PubMed  CAS  Google Scholar 

  7. Craig AM, Davey P, Malek M, et al. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. Pharmacoeconomics 1996; 10 (1): 79–92

    Article  PubMed  CAS  Google Scholar 

  8. Barnes J. Helicobacter pylori eradication up to date. Practitioner 1995; 239: 67–8

    PubMed  CAS  Google Scholar 

  9. Lerang F, Moum B, Haug JB, et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 1997; 92: 248–53

    PubMed  CAS  Google Scholar 

  10. Goodwin CS, Mendall MM, Northfield TC. Helicobacter pylori infection. Lancet 1997; 349: 265–9

    Article  PubMed  CAS  Google Scholar 

  11. Axon ATR, O’Moráin CA, Bardhan KD, et al. Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori. BMJ 1997; 314: 565–8

    Article  PubMed  CAS  Google Scholar 

  12. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med 1993; 328: 349–50

    Article  PubMed  CAS  Google Scholar 

  13. Penston JG, Wormsley KG. Maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 1992; 6: 3–29

    Article  PubMed  CAS  Google Scholar 

  14. Marshall BJ, Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1984; I: 1311–5

    Article  Google Scholar 

  15. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995; 9 (Suppl 2): 33–9

    PubMed  Google Scholar 

  16. Kuipers EJ, Thijs JC, Festen HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; (Suppl 2): 59–71

    Google Scholar 

  17. Clausen M, Franzmann M, Holst C, et al. Longitudinal study of influence of Helicobacter pylori on current risk of DU relapse. Scand J Gastroenterol 1992; 27: 421–6

    Article  PubMed  CAS  Google Scholar 

  18. Axon A, Bell G, Jones R, et al. Guidelines on appropriate indications for upper gastrointestinal endoscopy. BMJ 1995; 310: 853–6

    Article  PubMed  CAS  Google Scholar 

  19. Peterson WL. Current concepts: Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991; 324: 1043–8

    Article  PubMed  CAS  Google Scholar 

  20. Hosking SW, Ling TKW, Chung SCS, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without antiacid treatment: randomised controlled trial. Lancet 1994; 343: 508–10

    Article  PubMed  CAS  Google Scholar 

  21. Nomura A, Stemmermann G, Chyou P, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994; 120: 977–81

    PubMed  CAS  Google Scholar 

  22. Tytgat G, Noach L, Rauws E. Helicobacter pylori infection and DU disease. Gastroenterol Clin North Am 1993; 22: 127–39

    PubMed  CAS  Google Scholar 

  23. Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradication Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716–27

    PubMed  CAS  Google Scholar 

  24. Coghlan JG, Gilligan D, Humphries H, et al. Campylobacter pylori and recurrence of DUs: a 12 month follow-up study. Lancet 1987; II: 1109–11

    Article  Google Scholar 

  25. Zheng ZT, Wang ZY, Chu YX, et al. Double blind short-term trial of furazolidone in peptic ulcer. Lancet 1985; I: 1048–9

    Google Scholar 

  26. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of DU relapse after eradication of Campylobacter pylori. Lancet 1988; II: 1437–41

    Article  Google Scholar 

  27. Rauws E, Tytgat G. Cure of DU associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233–5

    Article  PubMed  CAS  Google Scholar 

  28. Hawkey CJ. Eradication of Helicobacter pylori should be pivotal in managing peptic ulceration. BMJ 1994; 309: 1570–2

    Article  PubMed  CAS  Google Scholar 

  29. Tytgat G. Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359–68

    Article  PubMed  CAS  Google Scholar 

  30. Bell GD, Powell KU, Bolton G, et al. Clinical and pharmacoeconomics evaluation of management strategies for DU disease. Br J Med Econ 1993; 6: 45–58

    Google Scholar 

  31. Briggs AH, Sculpher MJ, Logan RPH, et al. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.BMJ 1996; 312: 1321–5

    CAS  Google Scholar 

  32. Scrip Yearbook. Richmond (Surrey, England): PJB Publications Ltd, 1995

    Google Scholar 

  33. Scrip Yearbook. (Surrey, England): PJB Publications Ltd, 1996

    Google Scholar 

  34. Tytgat G. Peptic ulcer and Helicobacter pylori: eradication and relapse. Scand J Gastroenterol 1995; 210 Suppl.: 70–2

    Google Scholar 

  35. Penston JG, Crombie IK,Waugh NR, et al. Trends in morbidity and mortality from peptic ulcer disease: Tayside versus Scotland. Aliment Pharmacol Ther 1993; 7: 429–42

    Article  PubMed  CAS  Google Scholar 

  36. Wilhelmsen I, Berstad A. Quality of life and relapse of DU before and after eradication of Helicobacter pylori. Scand J Gastroenterol 1994; 29: 874–9

    Article  PubMed  CAS  Google Scholar 

  37. Phull PS, Ryder SD, Halliday D, et al. The economic and quality of life benefits of Helicobacter pylori eradication in chronic DU disease: a community based study. Postgrad Med J 1995; 71: 413–8

    Article  PubMed  CAS  Google Scholar 

  38. Reilly TG, Ayres RCS, Poxon V, et al. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 1995; 9: 483–91

    Article  PubMed  CAS  Google Scholar 

  39. Bell GD, Bate CM, Axon AT, et al. Symptomatic and endoscopic DU relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxicillin with or without metronidazole. Aliment Pharmacol Ther 1996; 10: 637–44

    Article  PubMed  CAS  Google Scholar 

  40. Phull PS, Halliday D, Price AB, et al. Absence of dyspeptic symptoms as a test for Helicobacter pylori eradication. BMJ 1996; 312: 349–50

    Article  PubMed  CAS  Google Scholar 

  41. British National Formulary. London: British Medical Association and The Pharmaceutical Press, 1996

  42. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxycillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of DU. N Engl J Med 1993; 328: 308–12

    Article  PubMed  CAS  Google Scholar 

  43. Adamek RJ, Opferkuch W, Wegener M. Modified short-term triple therapy - ranitidine, clarithromycin, and metronidazole for cure of Helicobacter pylori infection. Am J Gastroenterol 1995; 90: 168–9

    PubMed  CAS  Google Scholar 

  44. Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773–7

    Article  Google Scholar 

  45. Goddard A, Logan R. One-week low-dose triple therapy: new standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995; 7: 1–3

    PubMed  CAS  Google Scholar 

  46. De Boer WA, Driessen WMM, Potters VPJ, et al. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89: 1993–7

    PubMed  Google Scholar 

  47. De Boer W, Driessen W, Jansz A, et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995; 345: 817–20

    Article  PubMed  Google Scholar 

  48. McColl KEL, El-Nujumi A, Murray LS, et al. Assessment of symptomatic response as predictor ofHelicobacter pylori status following eradication therapy in patients with ulcer. Gut 1998; 42: 618–22

    Article  PubMed  CAS  Google Scholar 

  49. Labenz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442–7

    Article  PubMed  CAS  Google Scholar 

  50. Higgins G. European peptic ulcer treatment guidelines questioned. PharmacoEcon Outcomes News 1997; 6 (141): 3

    Google Scholar 

  51. Boyd EJ. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol 1996; 91: 1539–43

    PubMed  CAS  Google Scholar 

  52. Johnsson F, Joelsson B, Gudmundsson K, et al. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987; 22: 714–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Management, University of St Andrews, St Katherine’s West, The Scores, St Andrews, KY16 9AL, Scotland

    Manouche Tavakoli & Mo Malek

  2. Department of Clinical Pharmacology, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland

    Andrzej T. Prach & Frank E. Murray

  3. Department of Pathology, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland

    David Hopwood

  4. Department of Medical Microbiology, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland

    Bernard W. Senior

Authors
  1. Manouche Tavakoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrzej T. Prach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mo Malek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Hopwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bernard W. Senior
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Frank E. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manouche Tavakoli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tavakoli, M., Prach, A.T., Malek, M. et al. Decision Analysis of Histamine H2-Receptor Antagonist Maintenance Therapy Versus Helicobacter pylori Eradication Therapy. Pharmacoeconomics 16, 355–365 (1999). https://doi.org/10.2165/00019053-199916040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199916040-00004

Keywords

Search

Navigation